发布求助
文献互助 智能选刊 最新文献

THERAPEUTISCHE UMSCHAU最新文献

筛选
英文 中文
[Oral lichen planus - an overview of aetiology and treatment]. 口腔扁平苔藓——病因和治疗综述。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.007
Laurence Feldmeyer, Valérie G A Suter
{"title":"[Oral lichen planus - an overview of aetiology and treatment].","authors":"Laurence Feldmeyer, Valérie G A Suter","doi":"10.23785/TU.2025.04.007","DOIUrl":"https://doi.org/10.23785/TU.2025.04.007","url":null,"abstract":"<p><strong>Introduction: </strong>Oral lichen planus (OLP) is a chronic inflammatory, T cell-mediated autoimmune disease of the oral mucosa that primarily affects middle-aged women. A typical clinical feature is a network of white lines (Wickham's striae) on the buccal mucosa. In addition to asymptomatic forms, painful erosive-atrophic variants also occur, which require treatment. Diagnosis is usually clinical, but a biopsy may be needed if the presentation is atypical. In terms of differential diagnosis, drug reactions and contact hypersensitivities must be considered. The exact pathogenesis remains unclear, though immunologic, genetic, and viral factors (especially hepatitis C) are discussed. Topical corticosteroids are the first-line treatment. In therapy-resistant cases, options include tacrolimus, methotrexate (MTX), apremilast, or systemic corticosteroids. Maintaining good oral hygiene, eliminating potential triggers (e. g., amalgam), and tailoring therapy to individual symptoms are essential components of effective management. Due to the risk of malignant transformation to squamous cell carcinoma, regular follow-up is essential.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"130-134"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Escalation and de-escalation of therapy for high-risk melanomas]. [高危黑色素瘤的升级和降级治疗]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.008
Reinhard Dummer, Lara Valeska Maul, Egle Ramelyte, Joanna Mangana
{"title":"[Escalation and de-escalation of therapy for high-risk melanomas].","authors":"Reinhard Dummer, Lara Valeska Maul, Egle Ramelyte, Joanna Mangana","doi":"10.23785/TU.2025.04.008","DOIUrl":"https://doi.org/10.23785/TU.2025.04.008","url":null,"abstract":"<p><strong>Introduction: </strong>For a long time, advanced melanoma was a difficult-to-treat disease with no effective survival strategies. With the development of checkpoint inhibitors and kinase inhibitors in the 21st century, treatment options have improved considerably. Recent studies indicate that adjuvant therapy with anti-PD1-antibodies significantly improves the recurrence-free survival in stage IIB/C patients without lymph node involvement. However, the challenge is to identify the right patients for long-term treatment, as many could be cured by surgery alone. Neoadjuvant therapy, in which systemic treatment is administered before the surgical removal of the macroscopic lymph node metastases, has proven to be promising. Neoadjuvant approaches, particularly with anti-PD1-antibodies, can significantly reduce the recurrence rate. Additionally, histological analysis of tumor tissue after neoadjuvant therapy could help identify patients who do not require further adjuvant treatment, thereby reducing side effects and costs. However, the implementation of neoadjuvant therapy in clinical practice faces challenges, such as the lack of approval in Switzerland and the need for specialized histopathological assessments. Future research efforts should focus on developing criteria for patient selection and validating the role of histopathological examinations in prognosis. A de-escalation of therapeutic approaches could lead to more patient-centered, resource-efficient medicine.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"135-137"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatologische Brennpunkte für den Hausarzt. 皮肤科医生。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.001
Reinhard Dummer
{"title":"Dermatologische Brennpunkte für den Hausarzt.","authors":"Reinhard Dummer","doi":"10.23785/TU.2025.04.001","DOIUrl":"https://doi.org/10.23785/TU.2025.04.001","url":null,"abstract":"<p><strong>Introduction: </strong></p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"105"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Contemporary management of atopic dermatitis: from basic skincare to targeted systemic therapies]. [当代特应性皮炎的治疗：从基础护肤到靶向全身治疗]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.002
Claudia Lang, Matthias Möhrenschlager, Peter Schmid-Grendelmeier
{"title":"[Contemporary management of atopic dermatitis: from basic skincare to targeted systemic therapies].","authors":"Claudia Lang, Matthias Möhrenschlager, Peter Schmid-Grendelmeier","doi":"10.23785/TU.2025.04.002","DOIUrl":"https://doi.org/10.23785/TU.2025.04.002","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczema, and impaired skin barrier. In recent years we have seen significant advances in the treatment of AD, with the introduction of new topical and systemic therapies. In addition to basic therapy and classic topical steroids and calcineurin inhibitors other topical substances and for severe forms systemic biologics and Janus kinase inhibitors are now available. Therapy selection is individualized, level-based considering disease severity, and regarding comorbidities and patient preferences. This article provides an up-to-date overview of evidence-based therapeutic options, discusses their efficacy and safety, and offers an outlook on future developments.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"106-110"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The Spitz nevus is not a melanoma in childhood]. （斯皮兹痣不是儿童时期的黑色素瘤）。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.006
Mario Teufer, Reinhard Dummer
{"title":"[The Spitz nevus is not a melanoma in childhood].","authors":"Mario Teufer, Reinhard Dummer","doi":"10.23785/TU.2025.04.006","DOIUrl":"https://doi.org/10.23785/TU.2025.04.006","url":null,"abstract":"<p><strong>Introduction: </strong>The classic Spitz nevus is a benign, biologically stable melanocytic lesion in children and should not be equated with melanoma or its precursors. In contrast, Spitz tumors as a group represent a heterogeneous spectrum of melanocytic neoplasms, ranging from benign nevi to intermediate lesions with uncertain biological behavior and, rarely, malignant Spitz melanomas. Accurate classification relies on an integrative assessment of clinical, histological, and immunohistochemical features, complemented by molecular analyses in selected cases. Age-related risk stratification, growth behavior, architectural symmetry, and markers of maturation and proliferation are key determinants. The primary objective is not semantic categorization but rather a precise estimation of biological potential. This diagnostic approach helps to avoid overtreatment of stable lesions while enabling early detection of rare progressive cases. A structured, age-appropriate, and interdisciplinary diagnostic strategy is essential for informed and responsible clinical decision-making.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"124-129"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[What's new about cutaneous T-cell lymphoma?] 皮肤t细胞淋巴瘤有什么新进展？］
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.004
Andrea Roggo
{"title":"[What's new about cutaneous T-cell lymphoma?]","authors":"Andrea Roggo","doi":"10.23785/TU.2025.04.004","DOIUrl":"https://doi.org/10.23785/TU.2025.04.004","url":null,"abstract":"<p><strong>Introduction: </strong>Cutaneous T-cell lymphomas (CTCL) are rare skin-predominant lymphomas, with Mycosis fungoides being the most common subtype. In Europe, the incidence is about 0.3 per 100 000 patient years. The majority of patients are suffering from limited disease with a 5-year survival of 90 %. Clinically, skin lesions can mimic eczema or psoriasis, leading to delayed diagnosis. CTCL diagnosis requires a combination of clinical examination, skin biopsy with histopathological analysis and blood tests to assess systemic involvement. CTCL treatment is stage-dependent. Depending on the stage of the disease, local or systemic therapies can be used. Individually optimised combinations are common. Novel targeted therapies such as brentuximab vedotin and mogamulizumab have expanded the treatment landscape, offering more effective and personalized options. Allogeneic stem cell transplantation is the only curative approach. In CTCL, quality of life is often impaired due to chronic itching, fatigue, and stigmatizing skin lesions. Psychodermatologic care plays a key role in comprehensive patient support.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"117-120"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The importance of clinical-pathological correlation in dermatohistopathology]. [临床病理相关性在皮肤组织病理学中的重要性]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.005
Beda Mühleisen
{"title":"[The importance of clinical-pathological correlation in dermatohistopathology].","authors":"Beda Mühleisen","doi":"10.23785/TU.2025.04.005","DOIUrl":"https://doi.org/10.23785/TU.2025.04.005","url":null,"abstract":"<p><strong>Introduction: </strong>Correct and precise dermatohistopathologic diagnosis requires excellent histopathologic knowledge on the one hand, and on the other hand often a close correlation between clinical findings and histopathologic results. Clinicopathologic correlation (CPC) is essential to further improve the quality of histopathologic diagnosis and reduce the risk of misdiagnosis. This article describes the importance of CPC using examples of typical dermatoses that would be difficult to diagnose histologically alone and highlights the forms and chances of CPC.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"121-123"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Tattoo ink between beauty and risk: regulation in Switzerland, the EU and the USA]. [纹身墨水在美丽与风险之间：瑞士、欧盟和美国的监管]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.009
Thomas D Szucs
{"title":"[Tattoo ink between beauty and risk: regulation in Switzerland, the EU and the USA].","authors":"Thomas D Szucs","doi":"10.23785/TU.2025.04.009","DOIUrl":"https://doi.org/10.23785/TU.2025.04.009","url":null,"abstract":"<p><strong>Introduction: </strong>The growing popularity of tattoos highlights the importance of careful regulation of tattoo inks to minimise health risks. In Switzerland, tattoo inks are subject to strict legal requirements based on food legislation, which are designed to ensure that they are sterile and harmless. The European Union has significantly tightened restrictions on substances in tattoo inks through Regulation (EU) 2020/2081 in order to increase safety. In contrast, the USA regulate tattoo inks under the supervision of the Food and Drug Administration (FDA), but do not have specific pre-market controls for tattoo ink products. This comparison highlights different regulatory approaches in Switzerland, the EU and the USA and underlines the need for more harmonised global regulation to protect consumer health.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"138-140"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cutaneous reactions to drugs]. [对药物的皮肤反应]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-09-01 DOI: 10.23785/TU.2025.04.003
Ines Lederbogen, Barbara Meier-Schiesser
{"title":"[Cutaneous reactions to drugs].","authors":"Ines Lederbogen, Barbara Meier-Schiesser","doi":"10.23785/TU.2025.04.003","DOIUrl":"https://doi.org/10.23785/TU.2025.04.003","url":null,"abstract":"<p><strong>Introduction: </strong>Adverse drug reactions (ADRs) are a major global health problem with high morbidity and mortality rates. They are divided into two main types: the more common type A reactions, which are dose-dependent and usually predictable, and the rarer type B reactions, which occur independently of the dose and require an individual predisposition on the part of the patient and often pose a particular challenge in everyday clinical practice. The majority of cutaneous adverse drug reactions (ADRs) are uncomplicated. The most common are maculopapular exanthema, which typically represent a type IV hypersensitivity reaction. Serious cutaneous ADRs, on the other hand, are rare but can be potentially life-threatening. Skin changes associated with immune checkpoint inhibitors and other immunotherapies represent a separate entity within cutaneous drug reactions. Immune-related adverse events (irAE) are common in immunotherapy and are considered in many cases to be a correlate of a positive therapeutic response.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"111-116"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Secondary Headaches]. (二次头痛)。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2025-06-01 DOI: 10.23785/TU.2025.03.006
Laura Weichsel, Christoph Schankin
{"title":"[Secondary Headaches].","authors":"Laura Weichsel, Christoph Schankin","doi":"10.23785/TU.2025.03.006","DOIUrl":"https://doi.org/10.23785/TU.2025.03.006","url":null,"abstract":"<p><strong>Introduction: </strong>In clinical practice, correctly diagnosing headaches can be challenging due to the many differential diagnoses. It is particularly important to differentiate between the more common primary headache types, where the headache itself is the main condition, and secondary headaches, which may have potentially lifethreatening causes. The diagnostic approach initially focuses on identifying secondary headaches.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 3","pages":"94-99"},"PeriodicalIF":0.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信